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Summary. Allogeneic bone marrow transplantation 
(BMT) has been increasingly used for the treatment of 
both neoplastic and non-neoplastic disorders. However, 
serious obstacles currently limit the efficacy and thus 
more extensive use of BMT. These obstacles include: 
graft-versus-host disease (GVHD), relapse from the 
original tumor, and susceptibility of patients to 
opportunistic infections due to the immunosuppressive 
effects of the conditioning regimen.Overcoming these 
obstacles is complicated by dual outcome of existing 
regimens; attempts to reduce GVHD by depleting T cells 
from the graft, result in increased rates of tumor relapse 
and failure of engraftment. On the other hand, efforts to 
increase graft-versus-tumor (GVT) effects of the 
transplant also promote GVHD. In this review, the use of 
natural killer (NK) cells to overcome some of these 
obstacles of allogeneic BMT is evaluated. Adoptive 
immunotherapy using NK cells after allogeneic BMT 
has several potential advantages. First, NK cells can 
promote hematopoiesis and therefore engraftment by 
production of hematopoietic growth factors. Second, NK 
cells have been shown to prevent the incidence and 
severity of GVHD. This has been shown to be at least 
partially due to TGF-B, an immunosuppressive cytokine. 
Third, NK cells have been shown to augment numerous 
anti-tumor effects in animals after BMT suggesting a 
vital role of NK cells in mediating GVT effects. Finally, 
NK cells have been demonstrated to affect B cell 
recovery and function in mice. Therefore, understanding 
the mechanisms of beneficial effects of NK cells after 
BMT may lead to significant increases in the efficacy of 
this procedure. 
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Introduction 
Bone marrow transplantation (BMT) is currently 
used for patients with various malignant and non- 
malignant diseases including: severe anemias, acute and 
chronic leukemias, myelomas, and lymphomas, and its 
application is now extended to the treatment for some 
solid tumors such as breast cancer (Storb, 1995; 
Lebkowski et al., 1997; Ringden, 1997). However, 
serious problems currently limit the efficacy of BMT. 
Two primary sources of stem cells for transplantation are 
autologous, in which the host's own bone marrow or 
peripheral blood is used, and allogeneic, in which the 
host receives stem cells from another person. There are 
advantages and disadvantages associated with both 
autologous and allogeneic BMT. In autologous BMT, the 
level of engraftment is high, and the risk of graft-versus- 
host disease (GVHD) is low due to a lack of 
histocompatibility barriers. However, when autologous 
BMT is used for the treatment of cancer, the relapse 
rates from the original tumor is significantly higher 
compared to allogeneic BMT (Storb, 1995). In contrast, 
allogeneic BMT has the advantage of lower rate of 
tumor relapse due to a graft-versus-tumor (GVT) effect 
presumably mediated by immunocompetent donor T 
cells. However, GVHD caused by the same 
contaminating T cells in the graft and is a significant 
cause of morbidity (Ferrara and Deeg, 1991). T cell 
depletion from the graft reduces the incidence and 
severity of GVHD but also results in the higher rate of 
marrow graft failure, tumor relapse, and an increased 
occurrence of Epstein-Barr Virus (EBV) induced 
lymphomas (Storb, 1995). In addition, the conditioning 
regimen (i.e. total body irradiation and/or chemo- 
therapy) required for both autologous and allogeneic 
BMT to reduce the tumor burden and remove host cells 
capable of resisting the graft, leaves patients with severe 
immunosuppression and a susceptibility to opportunistic 
infections (Walter and Bowden, 1995). In spite of these 
drawbacks, the shortage of histocompatibility antigen 
(HLA) matched siblings among the patients who require 
BMT results in the increased use of marrow graft with 









